Atlas Trials

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Clinical trial NCT02129556 · COMPLETED

Trial details

NCT number
NCT02129556
Sponsor
ETOP IBCSG Partners Foundation
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2014-12-01
Primary completion
2017-08-04
Enrollment
58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.